These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19213566)

  • 1. Chemoprevention of oesophageal cancer and the AspECT trial.
    Das D; Chilton AP; Jankowski JA
    Recent Results Cancer Res; 2009; 181():161-9. PubMed ID: 19213566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.
    Jankowski JAZ; de Caestecker J; Love SB; Reilly G; Watson P; Sanders S; Ang Y; Morris D; Bhandari P; Brooks C; Attwood S; Harrison R; Barr H; Moayyedi P;
    Lancet; 2018 Aug; 392(10145):400-408. PubMed ID: 30057104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
    Tsibouris P; Hendrickse MT; Isaacs PE
    Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs.
    Morgan G; Vainio H
    Eur J Cancer Prev; 1998 Jun; 7(3):195-9. PubMed ID: 9696927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid suppression and chemoprevention in Barrett's oesophagus.
    Raj A; Jankowski J
    Dig Dis; 2004; 22(2):171-80. PubMed ID: 15383758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.
    Vaughan TL; Dong LM; Blount PL; Ayub K; Odze RD; Sanchez CA; Rabinovitch PS; Reid BJ
    Lancet Oncol; 2005 Dec; 6(12):945-52. PubMed ID: 16321762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics and prevention of oesophageal adenocarcinoma.
    Fitzgerald RC
    Recent Results Cancer Res; 2005; 166():35-46. PubMed ID: 15648181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention in Barrett's esophagus: A pill a day?
    Jankowski JA; Hooper PA
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):155-70. PubMed ID: 21112505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
    de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
    Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Wang F; Lv ZS; Fu YK
    Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.
    Morgan G
    Gut; 1996 May; 38(5):646-8. PubMed ID: 8707106
    [No Abstract]   [Full Text] [Related]  

  • 13. NSAIDs and the chemoprevention of colon and oesophageal cancer.
    Morgan GP
    Gut; 1995 Jan; 36(1):153-4. PubMed ID: 7890226
    [No Abstract]   [Full Text] [Related]  

  • 14. Aspirin and NSAIDs; benefits and harms for the gut.
    Thiagarajan P; Jankowski JA
    Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):197-206. PubMed ID: 22542157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
    Tan MC; El-Serag HB; Yu X; Thrift AP
    Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid reflux and oesophageal cancer.
    Nicholson A; Jankowski J
    Recent Results Cancer Res; 2011; 185():65-82. PubMed ID: 21822820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
    Spechler SJ; Barker PN; Silberg DG
    Aliment Pharmacol Ther; 2009 Jul; 30(2):138-45. PubMed ID: 19438416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
    Gatenby PA; Ramus JR; Caygill CP; Winslet MC; Watson A
    Eur J Cancer Prev; 2009 Sep; 18(5):381-4. PubMed ID: 19620873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis?
    Lagergren J
    Best Pract Res Clin Gastroenterol; 2006; 20(5):803-12. PubMed ID: 16997162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
    Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
    BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.